{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T01:50:28Z","timestamp":1778464228256,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["668036"],"award-info":[{"award-number":["668036"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["STOP-FSGS-01GM1901A"],"award-info":[{"award-number":["STOP-FSGS-01GM1901A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["TRR 130"],"award-info":[{"award-number":["TRR 130"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["AN372\/24-1"],"award-info":[{"award-number":["AN372\/24-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BO3755\/13-1"],"award-info":[{"award-number":["BO3755\/13-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BO3755\/3-1"],"award-info":[{"award-number":["BO3755\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BO3755\/9-1"],"award-info":[{"award-number":["BO3755\/9-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB\/TRR219"],"award-info":[{"award-number":["SFB\/TRR219"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB\/TRR57"],"award-info":[{"award-number":["SFB\/TRR57"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.kint.2021.01.024","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T03:38:16Z","timestamp":1613533096000},"page":"1331-1341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["A multicenter blinded preclinical randomized controlled trial on Jak1\/2 inhibition in MRL\/MpJ-Fas mice with proliferative lupus nephritis predicts low effect size"],"prefix":"10.1016","volume":"99","author":[{"given":"Yutian","family":"Lei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Sehnert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard E.","family":"Voll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conxita","family":"Jacobs-Cach\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"Soler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria D.","family":"Sanchez-Ni\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman D.","family":"B\u00fclow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Boor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2021.01.024_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.kint.2021.01.024_bib2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/BOR.0b013e3283025ed4","article-title":"The role of innate immunity in autoimmune tissue injury","volume":"20","author":"Allam","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.kint.2021.01.024_bib3","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/art.38006","article-title":"Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus","volume":"65","author":"Mok","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2021.01.024_bib4","first-page":"423","article-title":"The diagnosis and treatment of systemic lupus erythematosus","volume":"112","author":"Kuhn","year":"2015","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.kint.2021.01.024_bib5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.kint.2016.05.017","article-title":"A\u00a0pathophysiology-based approach to the diagnosis and treatment of lupus nephritis","volume":"90","author":"Anders","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.01.024_bib6","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013010026","article-title":"The pathogenesis of lupus nephritis","volume":"24","author":"Lech","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.01.024_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrneph.2017.85","article-title":"Redefining lupus nephritis: clinical implications of pathophysiologic subtypes","volume":"13","author":"Yu","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2021.01.024_bib8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1126\/science.aaa1724","article-title":"Journals unite for reproducibility","volume":"346","author":"McNutt","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.kint.2021.01.024_bib9","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1177\/0961203316652492","article-title":"A\u00a0critical review of clinical trials in systemic lupus erythematosus","volume":"25","author":"Mahieu","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2021.01.024_bib10","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/BOR.0b013e328363f4f2","article-title":"Challenges and opportunities in SLE clinical trials","volume":"25","author":"van Vollenhoven","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.kint.2021.01.024_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrneph.2015.206","article-title":"Hurdles to the introduction of new therapies for immune-mediated kidney diseases","volume":"12","author":"Anders","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2021.01.024_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol"},{"key":"10.1016\/j.kint.2021.01.024_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2018050515","article-title":"Quantity and reporting quality of kidney research","volume":"30","author":"Chatzimanouil","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.01.024_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1747-4949.2009.00386.x","article-title":"Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke","volume":"4","author":"Bath","year":"2009","journal-title":"Int J Stroke"},{"key":"10.1016\/j.kint.2021.01.024_bib15","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/STROKEAHA.113.000734","article-title":"A\u00a0concerted appeal for international cooperation in preclinical stroke research","volume":"44","author":"Dirnagl","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.kint.2021.01.024_bib16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/1074248411414155","article-title":"Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation","volume":"16","author":"Lefer","year":"2011","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.kint.2021.01.024_bib17","doi-asserted-by":"crossref","first-page":"299ra121","DOI":"10.1126\/scitranslmed.aaa9853","article-title":"Results of a preclinical randomized controlled multicenter trial (pRCT): anti-CD49d treatment for acute brain ischemia","volume":"7","author":"Llovera","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.kint.2021.01.024_bib18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.kint.2021.01.024_bib19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.kint.2021.01.024_bib20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2021.01.024_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/13543784.2019.1551358","article-title":"The Jakinibs in systemic lupus erythematosus: progress and prospects","volume":"28","author":"Mok","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.kint.2021.01.024_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000199","article-title":"Mouse models of lupus: what they tell us and what they don't","volume":"5","author":"Richard","year":"2018","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.kint.2021.01.024_bib23","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050","volume":"184","author":"Fridman","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2021.01.024_bib24","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.yrtph.2017.11.020","article-title":"Carcinogenicity assessment of baricitinib in Tg.rasH2 mice and Sprague-Dawley (Crl:CD) rats","volume":"92","author":"Carfagna","year":"2018","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.kint.2021.01.024_bib25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/art.21625","article-title":"The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials","volume":"54","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2021.01.024_bib26","doi-asserted-by":"crossref","first-page":"F783","DOI":"10.1152\/ajprenal.00279.2012","article-title":"Transcutaneous measurement of renal function in conscious mice","volume":"303","author":"Schreiber","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2021.01.024_bib27","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3389\/fimmu.2019.01223","article-title":"Interleukin-1\u03b2 inhibition for chronic kidney disease in obese mice with type 2 diabetes","volume":"10","author":"Lei","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2021.01.024_bib28","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1681\/ASN.2011010045","article-title":"Mdm2 promotes systemic lupus erythematosus and lupus nephritis","volume":"22","author":"Allam","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.01.024_bib29","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/ki.1984.75","article-title":"Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome","volume":"25","author":"Austin","year":"1984","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.01.024_bib30","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1038\/s41598-017-01894-y","article-title":"Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury","volume":"7","author":"Tato","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2021.01.024_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw8429","article-title":"Maternal gut microbiota in pregnancy influences offspring metabolic phenotype in mice","volume":"367","author":"Kimura","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.kint.2021.01.024_bib32","first-page":"i88","article-title":"Modelling clinical systemic lupus erythematosus: similarities, differences and success stories","volume":"56","author":"Celhar","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.kint.2021.01.024_bib33","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/13543784.2016.1162291","article-title":"Drugs in early clinical development for systemic lupus erythematosus","volume":"25","author":"Postal","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.kint.2021.01.024_bib34","first-page":"745647","article-title":"Genetic factors in systemic lupus erythematosus: contribution to disease phenotype","volume":"2015","author":"Ceccarelli","year":"2015","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.kint.2021.01.024_bib35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1124\/jpet.108.142711","article-title":"Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice","volume":"328","author":"Kulkarni","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.kint.2021.01.024_bib36","first-page":"496","article-title":"Modulation of glomerular structure and function in murine lupus nephritis by methylprednisolone and cyclophosphamide","volume":"124","author":"Kiberd","year":"1994","journal-title":"J\u00a0Lab Clin Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821002052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821002052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:59:11Z","timestamp":1758761951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253821002052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0085253821002052"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2021.01.024","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter blinded preclinical randomized controlled trial on Jak1\/2 inhibition in MRL\/MpJ-Faslpr mice with proliferative lupus nephritis predicts low effect size","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2021.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2021.01.021","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}